
Home / Team
Our Team
Medical, pharmaceutical, patent and industry experts across Taiwan, the United States and Japan.
Management Team
Benson Wang
Founder & Chairman, HOHO Biotech
Taiwan
- 2026HOHO was named one of the Global Top 8 in the Defense Technology category at SelectUSA 2026, the investment summit hosted by the U.S. government in the Washington, D.C. area.
- 2022Executive producer of Unleashing the Therapeutic Power of Hydrogen; author of Chapter 2, “The History of Hydrogen Medicine,” and co-author of Chapter 5, “Hydrogen Applications in Japan and Taiwan.”
- 2018–2026Led multiple HOHO H₂ capsule products through Taiwan FDA (TFDA) registration as capsule and tablet foods, obtaining registration numbers.
- 2017Founded HOHO Biotech and led the development of hydrogen-rich coral calcium (HRCC), the core technology of HOHO H₂ capsules.
- 2009–2016At the Chairman’s Office of Healthbanks Biotech Group, managed seven start-up ventures, including a therapeutic subunit-protein cervical cancer vaccine, animal vaccines, stem cells, a human organ bank, medical devices and new drugs.
- 2006–2008Managed intellectual property and technology transfer at the President’s Office, National Health Research Institutes (NHRI).
- 2000–2003Conducted genetic research on Alzheimer’s disease at the Department of Psychiatry, Taipei Veterans General Hospital.
- HOHO’s research has produced 37 publications to date.
- Google Scholar lists 26 peer-reviewed papers he has co-authored.
- His expertise spans patent and IP strategy, human clinical trials, clinical trial regulation and new venture development; he is a certified Project Management Professional (PMP).
- M.S. in Radiological Sciences, National Yang-Ming University; B.S. in Bioengineering, Tatung Institute of Technology; doctoral studies at the Graduate Institute of Medical Sciences, National Defense Medical Center.
Sources
Frank L. Douglas, Ph.D., M.D.
Former Executive Vice President and Chief Scientific Officer, Aventis
USA · Board Member
- 2022Wrote Preface 1 of Unleashing the Therapeutic Power of Hydrogen.
- 2011Caribbean Heritage Award for Entrepreneurship.
- 2010Named a “Rock Star of Science” by the Geoffrey Beene Foundation and GQ.
- 2009–2015President and CEO, Austen BioInnovation Institute (Ohio).
- Since 2009Mentor to Benson Wang, beginning with advice on the therapeutic subunit-protein cervical cancer vaccine program he then led.
- 2007Black History Makers Award.
- 2004Global Pharmaceutical R&D Director of the Year; Medal of the Faculty of Medicine, Goethe University Frankfurt.
- 2002NOBCChE Lifetime Achievement Award.
- 2001Global Pharmaceutical R&D Director of the Year.
- 1963Came to the United States as a Fulbright scholar.
- Guyanese-American physician-scientist and pharmaceutical R&D leader, born in British Guiana.
- B.S. in engineering from Lehigh University; Ph.D. in physical chemistry and M.D. from Cornell University.
- Completed his internship and residency in internal medicine at Johns Hopkins and a fellowship in neuroendocrinology at the National Institutes of Health (NIH); served as assistant professor of medicine at the University of Chicago.
- Spent more than two decades at Ciba-Geigy, Marion Merrell Dow, Hoechst Marion Roussel and Aventis. As Executive Vice President and Chief Scientific Officer of Aventis, he took part in developing 20+5 marketed drugs, including Allegra, Lantus, Lovenox and Taxotere.
- Professor of the Practice at the Harvard-MIT Division of Health Sciences and Technology, and founding Executive Director of the MIT Center for Biomedical Innovation.
- Recipient of the Weill Cornell Medical Alumni Achievement Award.
- Involved with HOHO since its founding.
Sources
Publications
Liang-Miin Tsai, Prof., M.D.
Superintendent, Tainan Municipal Hospital
Taiwan · Board Member
- 2022Wrote Preface 2 of Unleashing the Therapeutic Power of Hydrogen.
- 2007–2013Chair, Department of Internal Medicine, National Cheng Kung University Hospital.
- 2000–2004Superintendent, Chia-Li General Hospital.
- 1998Professor of Internal Medicine, National Cheng Kung University.
- 1988Joined National Cheng Kung University Hospital as one of its first physicians when the medical center opened.
- Cardiologist, professor of internal medicine and hospital administrator in Taiwan; currently Superintendent of Tainan Municipal Hospital.
- Graduated from the School of Medicine, Taipei Medical University.
- Performed the region’s first cardiac catheterization, balloon angioplasty and stent procedures.
- Former Director of the Emergency Department and Deputy Superintendent of National Cheng Kung University Hospital.
- Expertise in clinical cardiology, critical care medicine, echocardiography, interventional cardiology and hospital management.
- Leads HOHO’s clinical research team, which brings together professor-level physicians and department heads from Tainan Municipal Hospital, National Cheng Kung University Hospital and the NCKU College of Medicine, combining clinical and academic expertise.
Sources
- Tainan Municipal Hospital, Superintendent page ↗
- NCKU Hospital, Department of Internal Medicine, former chairs ↗
Publications
- Wu HT, et al. Drug Des Devel Ther 2025 (last author) — Gastroprotective effect of hydrogen capsule powder (HRCC) in a mouse model of peptic ulcer. PubMed ↗
- Wu HT, et al. Antioxidants 2024 (last author) — Hydrogen capsule powder (HRCC) improved fatty liver in mice via the gut microbiota and bile acid synthesis. PubMed ↗
- Wu HT, et al. Antioxidants 2022 (last author) — Hydrogen capsule powder (HRCC) alleviated acute alcohol intoxication in mice. PubMed ↗
Hsiu-Chih Chou (Sonia)
Licensed Pharmacist
Taiwan · Board Member
- 2022Wrote Chapter 1, “Global Human Trials and Regulatory Developments in Hydrogen Medicine,” of Unleashing the Therapeutic Power of Hydrogen.
- Licensed pharmacist with a long career in the pharmaceutical and biotech industries.
- At GlaxoSmithKline (GSK), served as Key Account Manager for hospital superintendent-level accounts and as Southern Region Sales Manager.
- Later served as a project manager at a Taiwanese biotech group, leading a new genetic testing business.
- Trained in pharmacy at Chia Nan University of Pharmacy & Science.
Sources
- Author profile, Chapter 1, Unleashing the Therapeutic Power of Hydrogen (2022)
- Unleashing the Therapeutic Power of Hydrogen (2022 edition), ISBN 9789860603521, Books.com.tw ↗
Hsiu-Ming Saunders, Ph.D., J.D.
Founder, IPC Intellectual Property Connections, Inc.
USA · Board Member
- 2022Co-wrote Section 6-3, “Technical Features of Hydrogen Capsules,” in Chapter 6 of Unleashing the Therapeutic Power of Hydrogen.
- U.S. patent attorney and licensed pharmacist; founder of IPC Intellectual Property Connections, Inc., a patent firm focused on biotechnology and pharmaceutical technologies.
- Ph.D. in Pharmacology and Toxicology, University of Mississippi Medical Center; J.D., William Mitchell College of Law.
- Her experience includes serving as a patent examiner at the U.S. Patent and Trademark Office (USPTO), patent liaison at Cargill, patent agent at Ella Cheong and at Wilkinson & Grist, IP project manager at Morris, Manning & Martin, and a role at the Bureau of Pharmaceutical Affairs, Department of Health, Taiwan.
- Her practice covers patent prosecution and legal counsel in protein chemistry, pharmacy, chemical processes, microbiology, immunology, molecular biology and medical devices. She has served research institutions and medical centers in Taiwan, including Academia Sinica, the National Health Research Institutes and the Industrial Technology Research Institute.
- The firm is built on efficient service, frequent and direct client communication, and cost-effective advice that helps innovations move from concept to market.
Source
- Author profile, Unleashing the Therapeutic Power of Hydrogen (2022)
Publications
- Yang HJ, et al. J Thorac Dis 2022 — Hydrogen inhalation improved cigarette smoke solution–induced COPD-like changes in mice. PubMed ↗
KOMATSU RIKO
Japan · Project Advisor · Production Management
- 2022Co-wrote Chapter 5, “Hydrogen Applications in Japan and Taiwan,” of Unleashing the Therapeutic Power of Hydrogen.
Yvonne Chen
Mentor · Founder, Ceres Capital
Taiwan · Mentor (TACC+)
- 2018Founded Ceres Capital.
- More than 20 years of experience in the international wireless communications and telecom industry and in technology investment.
- Began her career as a satellite communications systems engineer, then worked in Silicon Valley.
- Led HTC’s direct investment unit and served as a partner at WI Harper Group, managing the Alibaba Taiwan Entrepreneurship Fund II.
- Mentors start-ups through programs such as Taiwan Startup Stadium and TAcc+.
Sources
Expert Team
Po-Jen Hsiao, M.D., Ph.D.
Director, Division of Nephrology, and Director, Department of Internal Medicine, Taoyuan Armed Forces General Hospital
Taiwan · Medical Advisor
- 2023Senior author of a clinical study of hydrogen capsules (HRCC) in patients with metabolic syndrome (Frontiers in Nutrition, 2023).
- Nephrologist; currently Director of the Division of Nephrology and Director of the Department of Internal Medicine, Taoyuan Armed Forces General Hospital.
- Graduated from the National Defense Medical Center and earned a Ph.D. in Life Sciences from National Central University.
- Former attending nephrologist at Tri-Service General Hospital and one of its branch hospitals.
- Board-certified in internal medicine and an Associate Professor certified by the Ministry of Education; studied at the Institute of Medical Biometry and Informatics, Heidelberg University, Germany.
- Expertise in fluid and electrolyte disorders, hypertension, chronic kidney disease, kidney failure, hemodialysis and peritoneal dialysis.
Source
Publications
- Hsiao PJ, et al. Antioxidants 2026 (first author) — Review of molecular hydrogen therapy and chronic kidney disease–mineral and bone disorder (CKD-MBD). PubMed ↗
- Lu KC, et al. Int J Med Sci 2024 (last author) — Pilot observational study of oral hydrogen capsule (HRCC) supplementation and microinflammation in humans. PubMed ↗
- Chiu SH, et al. Front Nutr 2023 (last author) — Safety and lipid-lowering potential of oral hydrogen capsules (HRCC) in patients with metabolic syndrome. PubMed ↗
Ming-Chung Shen, M.D.
Rheumatology, Immunology and Allergy, Taoyuan Armed Forces General Hospital
Taiwan
- 2024Co-author of a pilot study of oral molecular hydrogen and microinflammation in humans (International Journal of Medical Sciences, 2024).
- 2023Co-author of a prospective study of hydrogen capsules (HRCC) in patients with metabolic syndrome (Frontiers in Nutrition, 2023).
- 2022Wrote Chapter 10, “Hydrogen in Rheumatology and Immunology,” of Unleashing the Therapeutic Power of Hydrogen.
- Rheumatologist and internist practicing in the Division of Rheumatology, Immunology and Allergy, Taoyuan Armed Forces General Hospital.
- Graduated from the School of Medicine, National Defense Medical Center; completed his internal medicine residency and chief residency at Taoyuan Armed Forces General Hospital, and served as an attending physician in internal medicine at one of its branch hospitals.
- Received advanced training in the Division of Rheumatology, Immunology and Allergy at Tri-Service General Hospital, where he is now a collaborating physician.
- Holds an M.S. from the School of Nutrition and Health Sciences, Taipei Medical University.
- Board-certified in rheumatology, internal medicine, musculoskeletal ultrasound in rheumatology and acupuncture; certified by the International Society for Clinical Densitometry (ISCD).
- His clinical focus includes autoimmune diseases such as systemic lupus erythematosus, Sjögren’s syndrome, ankylosing spondylitis and psoriasis, as well as rheumatoid arthritis, gout, osteoporosis, chronic musculoskeletal pain and allergic diseases.
- Co-author of several clinical and preclinical studies of hydrogen capsules (HRCC).
Source
Publications
- Lu KC, et al. Int J Med Sci 2024 — Pilot observational study of oral hydrogen capsule (HRCC) supplementation and microinflammation in humans. PubMed ↗
- Chiu SH, et al. Front Nutr 2023 — Safety and lipid-lowering potential of oral hydrogen capsules (HRCC) in patients with metabolic syndrome. PubMed ↗
- Yang HJ, et al. J Thorac Dis 2022 — Hydrogen inhalation improved cigarette smoke solution–induced COPD-like changes in mice. PubMed ↗
Szu-Han Chiu, M.D.
Chief, Division of Endocrinology and Metabolism, and Director, Civilian Medical Services, Taoyuan Armed Forces General Hospital
Taiwan
- 2024Co-author of a pilot study of oral molecular hydrogen and microinflammation in humans (International Journal of Medical Sciences, 2024).
- 2023First author of a prospective case series evaluating the safety and potential lipid-lowering effect of oral hydrogen capsules (HRCC) in patients with metabolic syndrome (Frontiers in Nutrition, 2023).
- 2017Published studies on glucose-lowering drugs and survival in diabetic dialysis patients (Clinical and Experimental Nephrology, 2017) and on telehealth home care supporting diabetes self-care (Journal of Medical Sciences, 2017).
- 2014Outstanding Teacher Award, Taoyuan Armed Forces General Hospital.
- 2009Co-author of the textbook Physiology Secrets (2009).
- Endocrinologist; currently Chief of the Division of Endocrinology and Metabolism and Director of Civilian Medical Services, Taoyuan Armed Forces General Hospital.
- Graduated from the School of Medicine, National Defense Medical Center. He has long practiced endocrinology and metabolism at Taoyuan Armed Forces General Hospital, serving as attending physician and Deputy Director of Civilian Medical Services before becoming division chief.
- Earlier served as an attending physician in endocrinology and metabolism at Armed Forces Hsinchu Hospital (now the Hsinchu Branch of Taoyuan Armed Forces General Hospital).
- His clinical focus includes diabetes, thyroid disease, parathyroid disease, hyperlipidemia, secondary hypertension, morbid obesity and metabolic syndrome, osteoporosis and other endocrine disorders.
- He has also published in the Journal of Internal Medicine of Taiwan and the Formosan Journal of Endocrinology and Metabolism.
Source
Publications
- Lu KC, et al. Int J Med Sci 2024 — Pilot observational study of oral hydrogen capsule (HRCC) supplementation and microinflammation in humans. PubMed ↗
- Chiu SH, et al. Front Nutr 2023 (first author) — Safety and lipid-lowering potential of oral hydrogen capsules (HRCC) in patients with metabolic syndrome. PubMed ↗
Feng-Cheng Liu, M.D., Ph.D.
Director, Division of Rheumatology, Immunology and Allergy, and Deputy Director, Department of Internal Medicine, Tri-Service General Hospital; Full-time Associate Professor, National Defense Medical University
Taiwan
- 2024Co-author of a pilot study of oral molecular hydrogen and microinflammation in humans (International Journal of Medical Sciences, 2024).
- 2023Co-author of a prospective study of hydrogen capsules (HRCC) in patients with metabolic syndrome (Frontiers in Nutrition, 2023).
- Rheumatologist; currently Director of the Division of Rheumatology, Immunology and Allergy and Deputy Director of the Department of Internal Medicine, Tri-Service General Hospital.
- Full-time Associate Professor, National Defense Medical University.
- Also an attending physician in general internal medicine at Tri-Service General Hospital and in rheumatology, immunology and allergy at one of its branch hospitals.
- Graduated in medicine from the National Defense Medical Center and earned a Ph.D. from its Graduate Institute of Medical Sciences.
- Completed his residency and chief residency in rheumatology and immunology, and served as chief resident in general internal medicine, at Tri-Service General Hospital.
- His clinical focus includes systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s syndrome, scleroderma, dermatomyositis, gout, osteoarthritis, ankylosing spondylitis and other rheumatic and immune diseases, as well as allergic conditions such as asthma, allergic rhinitis and drug or food allergy.
- Research specialty: Rheumatology and Immunology.
Source
Publications
Tsai-Kun Wu, M.D., Ph.D.
Attending Physician, Division of Nephrology, Tungs’ Taichung MetroHarbor Hospital
Taiwan
- 2025First author of a study showing that hydrogen-rich coral calcium powder (Coral Hydrate, HRCC) improved renal fibrosis by inhibiting indoxyl sulfate–induced, ROS-mediated NLRP3 inflammasome activation (European Journal of Pharmacology, 2025).
- Nephrologist at Tungs’ Taichung MetroHarbor Hospital, board-certified in internal medicine and nephrology.
- Trained at Linkou Chang Gung Memorial Hospital.
- At Tungs’ Taichung MetroHarbor Hospital, has served as an attending physician in general internal medicine and the intensive care unit, and as a research fellow in nephrology.
- His clinical focus includes acute and chronic kidney failure, hematuria, proteinuria, edema, hypertension, diabetes, hemodialysis, peritoneal dialysis, urinary tract infections and kidney transplantation.
- Associate Professor (project-based), Post-Baccalaureate Medicine, National Chung Hsing University; holds a Ph.D. in cancer biology and drug discovery.
- Principal investigator of multicenter clinical trials in chronic kidney disease and IgA nephropathy.
Sources
- Tungs’ Taichung MetroHarbor Hospital, Nephrology, physician profile ↗
- National Chung Hsing University, Post-Baccalaureate Medicine, clinical faculty ↗
Publications
- Wu TK, et al. Eur J Pharmacol 2025 (first author) — Hydrogen-rich coral calcium powder (Coral Hydrate, HRCC) suppressed indoxyl sulfate–induced NLRP3 inflammation and improved renal fibrosis. PubMed ↗
Chyou-Wei Wei, Ph.D.
Associate Professor, Department of Nutrition, HungKuang University
Taiwan
- Associate Professor in the Department of Nutrition at HungKuang University.
- Holds a Ph.D. from the Institute of Life Sciences, National Tsing Hua University, and a Ph.D. in Life Sciences from the National Defense Medical Center; conducted postdoctoral research at the Institute of Molecular Biology, Academia Sinica.
- Expertise in nutritional medicine, molecular nutrition, cell and molecular biology, and biochemistry.
- Her research focuses on how antioxidant nutrients protect kidney cells from drug- and toxin-induced injury, and she leads an industry–academia project on oral hydrogen capsules (HRCC) and drug-induced kidney cell toxicity.
Source
Lein-Ray Mo, M.D., MPH
Vice President, Show Chwan Health Care System
Taiwan
- 2022Wrote Chapter 9, “Using Hydrogen Capsules Alongside COVID-19 Vaccination,” of Unleashing the Therapeutic Power of Hydrogen.
- 2019Lifetime Achievement Award, Tainan Medical Association.
- 1990Became Superintendent of Tainan Municipal Hospital, serving the hospital for more than 30 years.
- 1988Joined Tainan Municipal Hospital when Show Chwan took over its operation, making it Taiwan’s first publicly owned, privately operated hospital.
- Gastroenterologist and hepatologist; currently Vice President of Show Chwan Health Care System, seeing patients in the Division of Gastroenterology and Hepatology at Tainan Municipal Hospital.
- Graduated from the College of Medicine, National Taiwan University; MPH, Tulane University (USA).
- Completed his residency and specialty training at National Taiwan University Hospital, where he became an attending physician, and later served as Chief of Internal Medicine at Show Chwan Memorial Hospital.
- Former Vice Superintendent for Medical Affairs and Chief of Gastroenterology and Hepatology at E-Da Hospital, Associate Professor at the National Taiwan University and National Cheng Kung University colleges of medicine, and President of the Taiwan Pancreas Society.
- Expert in biliary endoscopy and interventional treatment of liver cancer, and a long-time advocate of community screening and treatment for hepatitis B and C.
Sources
Hung-Tsung Wu, Ph.D.
Associate Professor, Department of Internal Medicine, National Cheng Kung University College of Medicine
Taiwan
- Earned his Ph.D. at the Institute of Basic Medical Sciences, National Cheng Kung University.
- Teaches metabolic physiology and obesity medicine.
- Author of preclinical studies of hydrogen capsules (HRCC) on fatty liver, peptic ulcer and alcohol intoxication.
Source
Publications
- Wu HT, et al. Drug Des Devel Ther 2025 (first author) — Gastroprotective effect of hydrogen capsule powder (HRCC) in a mouse model of peptic ulcer. PubMed ↗
- Wu HT, et al. Antioxidants 2024 (first author) — Hydrogen capsule powder (HRCC) improved fatty liver in mice via the gut microbiota and bile acid synthesis. PubMed ↗
- Wu HT, et al. Antioxidants 2022 (first author) — Hydrogen capsule powder (HRCC) alleviated acute alcohol intoxication in mice. PubMed ↗
Health Journalist & Bestselling Author
Kazuma Uwabe
Health Journalist and Author
Japan · Supervising Editor, Unleashing the Therapeutic Power of Hydrogen (2022)
- 2022Supervising editor of Unleashing the Therapeutic Power of Hydrogen.
- Since 2003Editor-in-chief, Health Information News.
- Since 2000Independent journalist and author.
- 1992Joined Health Industry Distribution News, a trade newspaper for the health industry.
- 1977Graduated from Meiji Gakuin University.
- 1954Born in Japan.
- Japanese journalist and author who has written on health and medicine for many years.
- Previously worked at an agency affiliated with the publisher Gakken.
- Drawing on two decades of on-site reporting in clinical settings, he has written books on cancer, dementia, intractable diseases and depression — key health issues of an aging society.
- Brings a Japanese perspective to HOHO’s expert team.
Selected books
- A Revolution for Zero Cancer Deaths (Hikaruland; in Japanese)
- Grasping the Mechanism That Heals Severe Dementia (Hikaruland, 2020; in Japanese)
- A New Dawn for Cancer Treatment (Kadensha, 2012; in Japanese)
- Mineral Therapy for Intractable Diseases (Chuo Art, 2009; in Japanese)
- Depression Can Vanish in 3 Days! (Hikaruland, 2020; in Japanese)
Sources